Neuroendocrine Brake for Type 2 Diabetes Mellitus
Primary Purpose
Diabetes
Status
Completed
Phase
Phase 4
Locations
Brazil
Study Type
Interventional
Intervention
ileal interposition with a sleeve gastrectomy
Sponsored by

About this trial
This is an interventional diagnostic trial for Diabetes
Eligibility Criteria
Inclusion Criteria:
- - Male and female between 18 and 65 years.
- BMI 25.1 - 34.9.
- Type 2 diabetic patients on oral anti-diabetic agents and/or insulin treatment for a minimum of 12 months prior the enrollment.
- Diagnosis of T2DM for at least 3 years.
- Patient has been under routine care of hte study physician or another physician that can supply a reliable medical record for at least 3 years.
- HbA1c >/ 7.5 documented for at least 3 months.
- Stable weight (nor significant weight change (>3%) over the 3 months prior to enrollment.
- Stable medication for at least one month prior to enrollment except for diabetes medications which should be stable for at least 3 months prior to enrollment.
- Ability and willingness to return for all scheduled visits and participate in recommended parameter setting and physician recommended medical/laboratory assessments.
Exclusion Criteria:
- Prior abdominal surgery, except laparoscopic cholecystectomy.
- Taking appetite suppressant.
- Severe eating disorders.
- Severe pulmonary, renal or cardiac disease.
- Obese due to a clinically diagnosed endocrine disorder.
- Subjects with impaired liver function.
- History of peptic ulcer disease.
- History of malignant disease.
- Use of prescription, over the counter or herbal weight loss products.
- Pregnant or planning on pregnancy while enrolled in study.
Sites / Locations
- Hospital de Especialidades
Outcomes
Primary Outcome Measures
Evaluate safety and efficacy of the ileal interposition associated with a sleeve gastrectomy and the ileal interposition associated with a diverted sleeve gastrectomy.
Secondary Outcome Measures
Evaluate neurohormonal effect in treating T2DM.
Improvement or control of blood glucose levels.
Improvement or control of comorbidities associated with T2DM.
Hormonal effect and effect of the operations on diabetes related and total mortality.
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT00450710
Brief Title
Neuroendocrine Brake for Type 2 Diabetes Mellitus
Official Title
Phase IV Study of Neuroendocrine Brake Surgical Procedure for Type 2 Diabetes Mellitus
Study Type
Interventional
2. Study Status
Record Verification Date
August 2014
Overall Recruitment Status
Completed
Study Start Date
March 2006 (undefined)
Primary Completion Date
September 2008 (Actual)
Study Completion Date
September 2009 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Medtronic - MITG
4. Oversight
5. Study Description
Brief Summary
Evaluation to determine the safety of two laparoscopic procedures to control T2DM.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Diabetes
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
40 (false)
8. Arms, Groups, and Interventions
Intervention Type
Procedure
Intervention Name(s)
ileal interposition with a sleeve gastrectomy
Primary Outcome Measure Information:
Title
Evaluate safety and efficacy of the ileal interposition associated with a sleeve gastrectomy and the ileal interposition associated with a diverted sleeve gastrectomy.
Secondary Outcome Measure Information:
Title
Evaluate neurohormonal effect in treating T2DM.
Title
Improvement or control of blood glucose levels.
Title
Improvement or control of comorbidities associated with T2DM.
Title
Hormonal effect and effect of the operations on diabetes related and total mortality.
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Eligibility Criteria
Inclusion Criteria:
- Male and female between 18 and 65 years.
BMI 25.1 - 34.9.
Type 2 diabetic patients on oral anti-diabetic agents and/or insulin treatment for a minimum of 12 months prior the enrollment.
Diagnosis of T2DM for at least 3 years.
Patient has been under routine care of hte study physician or another physician that can supply a reliable medical record for at least 3 years.
HbA1c >/ 7.5 documented for at least 3 months.
Stable weight (nor significant weight change (>3%) over the 3 months prior to enrollment.
Stable medication for at least one month prior to enrollment except for diabetes medications which should be stable for at least 3 months prior to enrollment.
Ability and willingness to return for all scheduled visits and participate in recommended parameter setting and physician recommended medical/laboratory assessments.
Exclusion Criteria:
Prior abdominal surgery, except laparoscopic cholecystectomy.
Taking appetite suppressant.
Severe eating disorders.
Severe pulmonary, renal or cardiac disease.
Obese due to a clinically diagnosed endocrine disorder.
Subjects with impaired liver function.
History of peptic ulcer disease.
History of malignant disease.
Use of prescription, over the counter or herbal weight loss products.
Pregnant or planning on pregnancy while enrolled in study.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Noreen A Gannon
Organizational Affiliation
Medtronic - MITG
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Aureo DePaula, MD
Organizational Affiliation
Hospital de Especialidades
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital de Especialidades
City
Goiania
Country
Brazil
12. IPD Sharing Statement
Learn more about this trial
Neuroendocrine Brake for Type 2 Diabetes Mellitus
We'll reach out to this number within 24 hrs